REGN241108P750000
- 0.50
- -0.89-64.03%
Regeneron Pharmaceuticals Newsroom
Sanofi, Regeneron Receive European Pediatric Approval for Throat Disease Treatment
Express News | Regeneron - Dupixent (Dupilumab) Approved in European Union as First and Only Medicine for Young Children With Eosinophilic Esophagitis
Truist Financial Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Announces Target Price $1,126
Regeneron Pharmaceuticals Insider Sold Shares Worth $844,610, According to a Recent SEC Filing
Upstream Bio Is New On NASDAQ, Can Potentially Beat AstraZeneca's Asthma Drug On Efficacy, Analysts Say
Is Weakness In Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock A Sign That The Market Could Be Wrong Given Its Strong Financial Prospects?
Bernstein Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Cuts Target Price to $1,110
This Is What Whales Are Betting On Regeneron Pharmaceuticals
Piper Sandler Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,195
TD Cowen Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,230
TD Cowen Reaffirms Their Buy Rating on Regeneron (REGN)
A Quick Look at Today's Ratings for Regeneron Pharmaceuticals(REGN.US), With a Forecast Between $800 to $1,195
Regeneron Pharma Is Maintained at Buy by Truist Securities
Bernstein Adjusts Price Target on Regeneron Pharmaceuticals to $1,110 From $1,135
Piper Sandler Maintains Overweight on Regeneron Pharmaceuticals, Lowers Price Target to $1195
This month, US stocks bull stock | soared 5 times in a year! MSTR plans to finance 42 billion to continue to increase its holdings of bitcoin; Explosive growth of users! The "American Tieba" Reddit soared more than 40% after the performance.
This month, the Dow Jones Industrial Average fell by 0.9% to 41,763.46 points; meanwhile, the S&P 500 Index declined by 1.86% to 5,705.45 points during the same period. The Nasdaq Index also saw a cumulative decline of 2.76% to 18,095.15 points.
Regeneron Pharmaceuticals Inc (REGN) Q3 2024 Earnings Call Highlights: Strong Revenue Growth ...
Decoding Regeneron Pharmaceuticals Inc (REGN): A Strategic SWOT Insight
Express News | Regeneron Pharmaceuticals Inc : Truist Securities Cuts Target Price to $1,126 From $1,137
Regeneron Shares Drop After Sales of Higher-Dose Eylea Miss Expectations